背景:我们以前的工作表明,在紫杉烷和蒽环类联合治疗中添加洛铂可以提高三阴性乳腺癌(TNBC)新辅助治疗的病理完全缓解率,并延长长期生存率。但该方案的治疗标志物尚不清楚.
方法:83名符合纳入标准的患者被纳入本事后分析。我们分析了新辅助化疗前血小板与淋巴细胞比值(PLR)和中性粒细胞与淋巴细胞比值(NLR)与多西他赛治疗后疗效和预后的关系。表柔比星,洛铂新辅助化疗方案。采用χ2检验和Cox回归分析PLR和NLR与病理完全缓解(tpCR)的关系,以及PLR和NLR与无事件生存率(EFS)和总生存率(OS)之间的关联,分别。
结果:PLR组的tpCR率为49.0%(25/51),显著高于PLR+组(25.0%[8/32],P=.032)。NLR组的tpCR率为49.1%(26/53),显著高于NLR+组(23.3%[7/30],P=.024)。PLR-NLR-(PLR-和NLR-)组的tpCR率为53.7%(22/41),显著高于PLR+/NLR+(PLR+或/和NLR+)组(26.1%[11/42];P=.012)。NLR+组的EFS和OS明显短于NLR-组(EFS的P=0.028;OS的P=0.047)。PLR-NLR-组患者的EFS比PLR+/NLR+组患者长(P=0.002)。
结论:PLR和NLR可用于预测紫杉烷新辅助治疗的疗效。蒽环类药物,和洛铂方案治疗TNBC患者,PLR和NLR值较低的患者tpCR率较高,长期预后较好.
BACKGROUND: Our previous work indicated that the addition of lobaplatin to combined therapy with taxane and anthracycline can improve the pathological complete response rate of neoadjuvant therapy for triple-negative breast cancer (TNBC) and lengthen long-term survival significantly, but the therapeutic markers of this regimen are unclear.
METHODS: Eighty-three patients who met the inclusion criteria were included in this post hoc analysis. We analyzed the association between platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) before neoadjuvant chemotherapy with the efficacy and prognosis after treatment with docetaxel, epirubicin, and lobaplatin neoadjuvant chemotherapy regimen. χ2 test and Cox regression were used to analyze the association between PLR and NLR with total pathologic complete response (tpCR), as well as the association between PLR and NLR with event-free survival (EFS) and overall survival (OS), respectively.
RESULTS: The tpCR rate in the PLR- group was 49.0% (25/51), which was significantly higher than that in the PLR+ group (25.0% [8/32], P = .032). The tpCR rate in the NLR- group was 49.1% (26/53), which was significantly higher than that in the NLR+ group (23.3% [7/30], P = .024). The tpCR rate of the PLR-NLR- (PLR- and NLR-) group was 53.7% (22/41), which was significantly higher than that of the PLR+/NLR+ (PLR+ or/and NLR+) group (26.1% [11/42]; P = .012). EFS and OS in the NLR+ group were significantly shorter than those in the NLR- group (P = .028 for EFS; P = .047 for OS). Patients in the PLR-NLR- group had a longer EFS than those in the PLR+/NLR+ group (P = .002).
CONCLUSIONS: PLR and NLR could be used to predict the efficacy of neoadjuvant therapy with the taxane, anthracycline, and lobaplatin regimen for patients with TNBC, as patients who had lower PLR and NLR values had a higher tpCR rate and a better long-term prognosis.